In a tumor-bearing mouse model, PFCR administration significantly prolonged pain relief beyond 10 h and increased CD8+ T cell infiltration into the tumor microenvironment, thereby potentiating the antitumor effects of cisplatin. The gene discussed is CD8A; the disease is neoplasm.